PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 12, 2019Thrombosis Journal20 citationsOpen Access

Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study

ELEmma Kirstine LaugesenLSLaila StærkNCNicholas Carlson

Structured PICO

Do NOACs reduce the risk of stroke/thromboembolism, major bleeding, myocardial infarction, or mortality in patients with atrial fibrillation and chronic kidney disease compared to VKAs?

P
Population
1,560 patients with a prior diagnosis of atrial fibrillation and chronic kidney disease not receiving dialysis (identified between 2011-2017).
I
Intervention
Non-vitamin K antagonist oral anticoagulants (NOACs)
C
Comparator
Vitamin-K antagonists (VKA)
O
Outcome
Incidents of stroke/thromboembolisms (TEs), major bleedings, myocardial infarctions (MIs), and all-cause mortalityhard clinical

In patients with atrial fibrillation and non-dialysis chronic kidney disease, NOACs are associated with a lower risk of major bleeding compared to VKAs, with similar effectiveness for stroke prevention.

Abstract

BACKGROUND: We aimed to compare effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin-K antagonists (VKA) in atrial fibrillation (AF) patients with chronic kidney disease (CKD) not receiving dialysis. METHODS: By using personal identification numbers, we cross-linked individual-level data from Danish administrative registries. We identified every citizen with a prior diagnosis of AF and CKD who initiated NOAC or VKA (2011-2017). An external analysis of 727 AF patients with CKD (no dialysis) was performed to demonstrate level of kidney function in a comparable population. Study outcomes included incidents of stroke/thromboembolisms (TEs), major bleedings, myocardial infarctions (MIs), and all-cause mortality. We used Cox proportional hazards models to determine associations between oral anticoagulant treatment and outcomes. RESULTS: Of 1560 patients included, 1008 (64.6%) initiated VKA and 552 (35.4%) initiated NOAC. In a comparable population we found that 95.3% of the patients had an estimated glomerular filtration rate (eGFR) < 59 mL/min. Patients treated with NOAC had a significantly decreased risk of major bleeding (hazard ratio (HR): 0.47, 95% confidence interval (CI): 0.26-0.84) compared to VKA. There was not found a significant association between type of anticoagulant and risk of stroke/TE (HR: 0.83, 95% CI: 0.39-1.78), MI (HR: 0.45, 95% CI: 0.18-1.11), or all-cause mortality (HR: 0.99, 95% CI: 0.77-1.26). CONCLUSION: NOAC was associated with a lower risk of major bleeding in patients with AF and CKD compared to VKA. No difference was found in risk of stroke/TE, MI, and all-cause mortality.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Laugesen et al. (2019) studied this question.

synapsesocial.com/papers/6a714fcce36a167817e324cehttps://doi.org/10.1186/s12959-019-0211-y
Ask AI
Helpful
Bookmark
Share
View Full Paper